RESOURCE USE AND ASSOCIATED COSTS OF LONG ACTING INJECTABLE ANTIPSYCHOTICS- A RAMQ DATABASE ANALYSIS

Author(s)

Lachaine J¹, Lapierre M¹, Abdalla N², Rouleau A³, Stip E⁴
¹University of Montreal, Montreal, QC, Canada, ²Lundbeck Canada Inc., Montreal, QC, Canada, ³Lundbeck SAS, Global Epidemiology, Issy-les-Moulineaux, France, ⁴, Montreal, QC, Canada

Presentation Documents

PMH40--strong-u-lachaine-j-u-sup-1-sup-strong-lapierre-m-sup-1-sup-abdalla-n-sup-2-sup-rouleau-a-sup-3-sup-stip-e-sup-4-sup-br-sup-1-sup-university-of-montreal-montreal-qc-canada-sup-2-sup-lundbeck-canada-inc-montreal-qc-canada-sup-3-sup-lu ...

OBJECTIVES: The purpose of this study was to describe the resource use before, and after, initiation of long-acting injectable antipsychotics (LAI-AP) using the provincial public drug reimbursement program database of the Régie de l’assurance maladie du Québec (RAMQ). METHODS: Patients who were incident users (no use in the previous 12 months) of a LAI-AP prescribed between January 1^st

Conference/Value in Health Info

2014-05, ISPOR 2014, Palais des Congres de Montreal

Value in Health, Vol. 17, No. 3 (May 2014)

Code

PMH40

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Mental Health

Presentation